---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088710"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:41:11.386968+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health: Revita shows 92% weight maintenance post-GLP-1; Rejuva prevents obesity in mice

## Summary
- 12 of 13 Revita participants maintained or lost weight at 3 months after stopping GLP-1; median weight stable (0.46% change).
- No serious adverse events with Revita; REMAIN-1 Midpoint cohort data expected Q3 2025 and Pivotal cohort H2 2026.
- Rejuva single dose prevented obesity and hyperglycemia in high-fat diet mice; 20% weight reduction and 38% glucose decrease.
- Rejuva RJVA-001 progressing toward first-in-human studies; preliminary clinical data anticipated in 2026.

## SEC filing metadata
- accession: 0000950170-25-088710
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017025088710/0000950170-25-088710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017025088710/guts-20250623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088710
- JSON: https://secwatch.observer/filing/0000950170-25-088710.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.